124 related articles for article (PubMed ID: 7127662)
1. Metabolism of high doses of cyclophosphamide.
Milsted RA; Jarman M
Cancer Chemother Pharmacol; 1982; 8(3):311-3. PubMed ID: 7127662
[TBL] [Abstract][Full Text] [Related]
2. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide.
Boddy AV; Furtun Y; Sardas S; Sardas O; Idle JR
J Natl Cancer Inst; 1992 Nov; 84(22):1744-8. PubMed ID: 1433359
[TBL] [Abstract][Full Text] [Related]
3. Determination of cyclophosphamide metabolites by gas chromatography and thermionic specific detection. Interindividual differences in hepatic biotransformation of cyclophosphamide in man in vitro.
Sessink PJ; Vaes WH; van den Broek PH; Noordhoek J; Bos RP
J Chromatogr B Biomed Appl; 1995 Nov; 673(2):205-12. PubMed ID: 8611954
[TBL] [Abstract][Full Text] [Related]
4. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients.
Hadidi AH; Coulter CE; Idle JR
Cancer Res; 1988 Sep; 48(18):5167-71. PubMed ID: 3409242
[TBL] [Abstract][Full Text] [Related]
5. [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].
Wagner T; Heydrich D; Voelcker G; Hohorst HJ
J Cancer Res Clin Oncol; 1980 Jan; 96(1):79-92. PubMed ID: 7358774
[TBL] [Abstract][Full Text] [Related]
6. The effect of cimetidine on cyclophosphamide metabolism in rabbits.
Anthony LB; Long QC; Struck RF; Hande KR
Cancer Chemother Pharmacol; 1990; 27(2):125-30. PubMed ID: 2249327
[TBL] [Abstract][Full Text] [Related]
7. Comparative metabolism of 2-[bis(2-chloroethyl)amino]tetrahydro-2-H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans.
Jarman M; Milsted RA; Smyth JF; Kinas RW; Pankiewicz K; Stec WJ
Cancer Res; 1979 Jul; 39(7 Pt 1):2762-7. PubMed ID: 445480
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of the antimitotic properties of cyclophosphamide and its biotransformation products on meristema plant cells and animal cells in in vitro culture].
Deysson G; Adolphe M; Semont H
C R Seances Soc Biol Fil; 1981; 175(2):182-6. PubMed ID: 6454464
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide metabolism in children.
Yule SM; Boddy AV; Cole M; Price L; Wyllie R; Tasso MJ; Pearson AD; Idle JR
Cancer Res; 1995 Feb; 55(4):803-9. PubMed ID: 7850793
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients.
Tasso MJ; Boddy AV; Price L; Wyllie RA; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1992; 30(3):207-11. PubMed ID: 1628369
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.
Busse D; Busch FW; Bohnenstengel F; Eichelbaum M; Fischer P; Opalinska J; Schumacher K; Schweizer E; Kroemer HK
J Clin Oncol; 1997 May; 15(5):1885-96. PubMed ID: 9164199
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
[TBL] [Abstract][Full Text] [Related]
13. Teratogenicity of cyclophosphamide metabolites: phosphoramide mustard, acrolein, and 4-ketocyclophosphamide in rat embryos cultured in vitro.
Mirkes PE; Fantel AG; Greenaway JC; Shepard TH
Toxicol Appl Pharmacol; 1981 Apr; 58(2):322-30. PubMed ID: 7245204
[No Abstract] [Full Text] [Related]
14. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide.
Mouridsen HT; Faber O; Skovsted L
Cancer; 1976 Feb; 37(2):665-70. PubMed ID: 1253102
[TBL] [Abstract][Full Text] [Related]
15. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites.
Boyd VL; Robbins JD; Egan W; Ludeman SM
J Med Chem; 1986 Jul; 29(7):1206-10. PubMed ID: 3543359
[TBL] [Abstract][Full Text] [Related]
16. Relative mutagenicity of some urinary metabolites of the antitumor drug cyclophosphamide.
Balbinder E; Reich CI; Shugarts D; Keogh J; Fibiger R; Jones T; Banks A
Cancer Res; 1981 Jul; 41(7):2967-72. PubMed ID: 7018675
[TBL] [Abstract][Full Text] [Related]
17. [Effective levels of cyclophosphamide and metabolites in pleural effusions during intravenous therapy (author's transl)].
Wagner T; Heydrich D
Arzneimittelforschung; 1982; 32(5):566-8. PubMed ID: 7201835
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.
Wilkinson PM; O'Neill PA; Thatcher N; Lucas SB
Cancer Chemother Pharmacol; 1983; 11(3):196-9. PubMed ID: 6640827
[TBL] [Abstract][Full Text] [Related]
19. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.
Schuler U; Ehninger G; Wagner T
Cancer Chemother Pharmacol; 1987; 20(3):248-52. PubMed ID: 3315284
[TBL] [Abstract][Full Text] [Related]
20. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
